A ratiometric fluorescence assay for acetylcholinesterase activity and inhibitor screening based on supramolecular assembly induced monomer–excimer emission transition of a perylene probe

He, Chunhua; Zhou, Huipeng; Hussain, Ejaz; Zhang, Yunyi; Li, Yunhui; Ma, Yuhong; Yu, Cong

doi:10.1039/c8ra01274a

Cited by 8 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it has great practical significance to create selective and sensitive probes for the detection of AChE. He and co-workers [ 72 ] employed 10 to construct a sensitive ratiometric fluorescence probe for the assay of AChE activity based on the monomer–excimer transition of probe 10 ( Figure 25 ). The probe mechanism is as follows: probe 10 mainly existed in a monomer state in a buffer solution with two fluorescence peaks at 548 nm and 587 nm, respectively, aggregated to supramolecular assemblies by mixture with lauroylcholine (employed as the substrate of AChE) and lauric acid, resulting in a redshifted excimer fluorescence at 680 nm.…”

Section: Fluorescent Probes and Their Biological Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Excimer-Based Fluorescence Probes for Biological Applications

Chen

2022

Molecules

View full text Add to dashboard Cite

The fluorescent probe is a powerful tool for biological sensing and optical imaging, which can directly display analytes at the molecular level. It provides not only direct visualization of biological structures and processes, but also the capability of drug delivery systems regarding the target therapy. Conventional fluorescent probes are mainly based on monomer emission which has two distinguishing shortcomings in practice: small Stokes shifts and short lifetimes. Compared with monomer-based emission, excimer-based fluorescent probes have large Stokes shifts and long lifetimes which benefit biological applications. Recent progress in excimer-based fluorescent sensors (organic small molecules only) for biological applications are highlighted in this review, including materials and mechanisms as well as their representative applications. The progress suggests that excimer-based fluorescent probes have advantages and potential for bioanalytical applications.

show abstract

Section: Fluorescent Probes and Their Biological Applicationsmentioning

confidence: 99%

“… ( a ) Fluorescence response of probe 10 (10 μM) in MOPS (pH 7.4) solution with lauroylcholine (130 μM) and lauric acid (300 μM) to AChE (5–250 mU/mL). ( b ) Plot of F monomer / F excimer (I M /I E ) value vs. AChE concentration (5–250 mU/mL) [ 72 ]. …”

Section: Figurementioning

confidence: 99%

Recent Advances in Excimer-Based Fluorescence Probes for Biological Applications

Chen

2022

Molecules

View full text Add to dashboard Cite

show abstract

“…However, this technique has not been applied to investigate the biosensing of AChE in the AD brain model. [133] For an excellent discrimination of BChE over AChE, Liu et al developed three rational NIR fluorophores (probes 1, 2, and 3). Among these, probe 3 (termed as BChE-NIRFP and referred to as probe 120 in this paper), exhibited a superb "signal-on" property to detect BChE enzyme in zebrafish, human cells, and the AD mouse model ( Figure 19F).…”

Section: Acetylcholinesterase and Butyrylcholinesterasementioning

confidence: 99%

Section: Reactive Oxygen Species (Ros)/reactive Nitrogen Species (Rns)mentioning

confidence: 99%

Fluorescent Diagnostic Probes in Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

Both chronic and acute neurodegenerative diseases have been associated with high morbidity and mortality, along with the death of neurons in different areas of the brain, and there are few or no effective curative therapy options for treatment of patients. [3,4] These disorders are a major cause of concern for the health and quality of life in the aging society, since age is the greatest risk factor for neurodegenerative disease. [5] The World Health Organization has predicted that in next 20 years neurodegenerative disease will become the second most common cause of mortality after cardiovascular disease. [6] Neurodegenerative processes begin long before their clinical symptoms are evident, and evolve for years slowly and irreversibly. Hence, there is an urgent need to diagnose neurodegenerative disease as early as possible and to distinguish between different neurodegenerative disorders with shared and unique symptoms to facilitate decision making regarding choice of treatment. Timely diagnosis is important for the adoption of therapeutic modalities in clinical trials prior to moderate dementia exhibition, to appraise and apply antidotes to maximally preserve the cognitive functions or to slow down the course of these disorders. The ability to analyze and identify risk factors for cognitive deficit would represent an extraordinary advancement in the field of dementia. [5] The main modern diagnostic technologies for the early examination of neurodegenerative disease pathology, neuroimaging techniques, include radioligandsbased positron emission tomography (PET), 3D single-photon emission-computed tomography (SPECT), and structural magnetic resonance imaging (MRI). Although PET and SPECT are the most used imaging techniques for neurodegenerative diseases, their application is limited by high cost, involvement of hazardous radiolabeled compounds, need for sophisticated instruments, and application of complex data acquisition and analysis protocols. The MRI technique has relatively low spatial resolution as well as intrinsically poor sensitivity to distinguish morphological differences between disease biomarkers and the surrounding tissue. Recently, fluorescence diagnosis technology has become an attractive and potential alternative to diagnose and probe the progression of neurodegenerative diseases, because of being rapid, noninvasive, sensitive, simple, real-time, low-cost, and high-resolution in nature. [7] There are several uses for Neurodegenerative diseases are debilitating disorders that feature progressive and selective loss of function or structure of anatomically or physiologically associated neuronal systems. Both chronic and acute neurodegenerative diseases are associated with high morbidity and mortality along with the death of neurons in different areas of the brain; moreover, there are few or no effective curative therapy options for treating these disorders. There is an urgent need to diagnose neurodegenerative disease as early as possible, and to distinguish between different disorders with overlap...

show abstract

A colorimetric assay for acetylcholinesterase activity and inhibitor screening based on the thiocholine–induced inhibition of the oxidative power of MnO2 nanosheets on 3,3′,5,5′–tetramethylbenzidine

Sun

Tan

2018

Microchim Acta

View full text Add to dashboard Cite

The authors describe a colorimetric method for the determination of the activity of acetylcholinesterase (AChE). Manganese dioxide (MnO) nanosheets directly reacts with 3,3',5,5'-tetramethylbenzidine (TMB) in the absence of hydrogen peroxide (HO). This leads to the formation of a blue product (oxTMB) with an absorption peak at 652 nm. If AChE hydrolyzes its substrate acetylthiocholine chloride, thiocholine is formed which blocks the oxidative power of the MnO nanosheets. Hence, oxTMB will not be formed. The decreased absorbance is directly related to the AChE activity in the 0.01-1.0 mU·mL range. The detection limit is 0.01 mU·mL and the relative standard deviation is 1.2% (for n = 11 at 0.5 mU·mL). The method was also applied to screen for inhibitors of AChE. Graphical abstract Based on the oxidizing properties of manganese dioxide nanosheets (MnO nanosheets), we report a colorimetric method for determining acetylcholinesterase activity with the chromogenic substrate 3,3',5,5'-tetramethylbenzidine (TMB).

show abstract

A ratiometric fluorescence assay for acetylcholinesterase activity and inhibitor screening based on supramolecular assembly induced monomer–excimer emission transition of a perylene probe

Abstract: The PDI-DHA can aggregate to form supramolecular assemblies when mixed with lauroylcholine and lauric acid, and is employed as a ratiometric fluorescence probe for the detection of AChE activity.

Cited by 8 publications

References 47 publications

Recent Advances in Excimer-Based Fluorescence Probes for Biological Applications

Recent Advances in Excimer-Based Fluorescence Probes for Biological Applications

Fluorescent Diagnostic Probes in Neurodegenerative Diseases

A colorimetric assay for acetylcholinesterase activity and inhibitor screening based on the thiocholine–induced inhibition of the oxidative power of MnO2 nanosheets on 3,3′,5,5′–tetramethylbenzidine

Contact Info

Product

Resources

About